Targeting the NLRP3 inflammasome for SSc therapy has yet to be sufficiently explored, but promising results from using NLRP3 inhibition in cases of pulmonary fibrosis—well as fibrosis in the liver, myocardium and kidney—indicate the potential of using similar inhibitors to reduce the significant fibrosis associated with SSc [78]. Here, NLRP3 is linked to systemic sclerosis.